Cardiorenal-anemia syndrome and iron deficiency: new challenges in prevention and treatment

7th International Congress of Cardionephrology KARNEF (2025) [pp. 163-173]

AUTHOR(S) / AUTOR(I): Fulvio Floccari

Download Full Pdf   

DOI: 10.46793/KARNEF25.170F

ABSTRACT / SAŽETAK:

KEYWORDS / KLJUČNE REČI:

REFERENCES / LITERATURA:

  1. Sheftel AD, Mason AB, Ponka P. The long history of iron in the Universe and in health and disease. Biochim Biophys Acta. 2012 Mar;1820(3):161-87.
  2. Fenton HJH. The oxidation of tartaric acid in presence of iron. Chem Soc Proc. 1893;9:113.
  3. Mc Ccord JM et al. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244:6049–6055.
  4. Busacchi V. [Vincenzo Menghini and the discovery of iron in the blood] Bull Sci Med (bologna) 1958;130:202–205.
  5. Brumberg JJ. Chlorotic girls, 1870–1920: a historical perspective on female adolescence. child dev. 1982;53:1468–147.
  6. Blaud P. sur les maladies chlorotiques, et sur un mode de traitement specifique dans ces affections. Rev Med Franc Etrang. 1832;45:341–367. 
  7. Mc Cance RA, Widdowson EM. The absorption and excretion of iron following oral and intra-venous administration. J Physiol. 1938;94:148–154. 
  8. Bonnet JD et al. Rate of loss of radioiron from mouse and man. am J Physiol. 1960;198:784–786.
  9. Hahn PF et al. Radioactive iron absorption by gastro-intestinal tract: influence of anemia, anoxia, and antecedent feeding distribution in growing dogs. J Exp Med. 1943;78:169–188.
  10. Koeller DM et al, Proc Natl Acad Sci US A. 1989;86:3574–3578.
  11. Muckenthaler mu et al, Ann Rev Nutr. 2008;28:197–213.
  12. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008; 15: 169–175.[DOI] [PubMed] [Google Scholar]
  13. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–1023.
  14. Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol. 2009;296:H585–H593.
  15. Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 2015;13:533–545.
  16. Lakhal-Littleton S, Wolna M, Carr CA, Miller JJJ, Christian HC, Ball V, Santos A, Diaz R, Biggs D, Stillion R, Holdship P, Larner F, Tyler DJ, Clarke K, Davies B, Robbins PA. Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc Natl Acad Sci. 2015;112:3164–3169.
  17. Lakhal-Littleton S, Wolna M, Chung YJ, Christian HC, Heather LC, Brescia M, Ball V, Diaz R, Santos A, Biggs D, Clarke K, Davies B, Robbins PA (2016) An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. Elife 5. 10.7554/eLife.19804
  18. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106:1092–1097.
  19. Anderson CP, Shen M, Eisenstein RS, Leiboldac EA  (2012) Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta – Mol Cell Res 1823:1468–1483.
  20. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian Iron metabolism. Cell. 2010;142:24–38.
  21. Haddad S, Wang Y, Galy B, et al. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur heart J. 2016;38:ehw333. 
  22. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872–1880.
  23. Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, Zannad F, Laperche T, Leclercq C, Concas V, Duvillié L, Darné B, Anker S, Mebazaa A. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16:984–991.
  24. Núñez J, Comín-Colet J, Miñana G, Núñez E, Santas E, Mollar A, Valero E, García-Blas S, Cardells I, Bodí V, Chorro FJ, Sanchis J. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18:798–802.
  25. Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mito-chondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19(4): 522–530
  26. Kasztura M, Dzięgała M, Kobak K, Bania J, Mazur G, Banasiak W, Ponikowski P, Jankowska EA. Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiol Pol. 2017;75:267–275. doi: 10.5603/KP.a2016.0155.[DOI] [PubMed] [Google Scholar]
  27. Dziegala M, Kasztura M, Kobak K, Bania J, Banasiak W, Ponikowski P, Jankowska EA. Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. Mol Med Rep. 2016;14:3969–3977.
  28. Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzóska K, Piotrowski W, Rywik TM, Danko B, Polkowska-Motrenko H, Różański JM, Kruszewski M. Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol. 2012;159:47–52.
  29. Nagao M, Matsuo Y, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S, Abe K, Mukai Y, Higo T, Yabuuchi H, Takemura A, Yoshiura T, Sunagawa K, Honda H. Quantification of myocardial Iron deficiency in nonischemic heart failure by cardiac T2* magnetic resonance imaging. Am J Cardiol. 2014;113:1024–1030.
  30. Nagao M, Baba S, Yonezawa M, Yamasaki Y, Kamitani T, Isoda T, Kawanami S, Maruoka Y, Kitamura Y, Abe K, Higo T, Sunagawa K, Honda H. Prediction of adverse cardiac events in dilated cardiomyopathy using cardiac T2* MRI and MIBG scintigraphy. Int J Cardiovasc Imaging. 2015;31:399–407.
  31. Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, García-Blas S, Santas E, Agüero J, Chorro FJ, Sanchis J, López-Lereu MP. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Hear Fail. 2016;3:293–298. 
  32. Terrovitis JV, Kaldara E, Ntalianis A, Sventzouri S, Kapelios C, Barbarousi D, Matsouka C, Nanas JN. Intravenous Iron alone is equally effective with the combination of Iron and erythropoietin for the treatment of Iron-deficiency Anemia in advanced heart failure. J Am Coll Cardiol. 2012;60:2255–2256.
  33. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015;17:248–262. doi: 10.1002/ejhf.236.[DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, for the NHLBI Heart Failure Clinical Research Network Effect of Oral Iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and Iron deficiency. JAMA. 2017;317:1958–1966.
  35. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators Ferric Carboxymaltose in patients with heart failure and Iron deficiency. N Engl J Med. 2009;361:2436–2448. doi: 10.1056/NEJMoa 0908355.[DOI] [PubMed] [Google Scholar]
  36. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, for the CONFIRM-HF Investigators Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–668. doi: 10.1093/eurheartj/ehu385.[DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail. 2013;15:1267–1276
  38. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous Iron alone for the treatment of Anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–1227. doi: 10.1016/j.jacc.2006.07.015.[DOI] [PubMed] [Google Scholar]
  39. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous Iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–1665. doi: 10.1016/j.jacc.2007.07.029.[DOI] [PubMed] [Google Scholar]
  40. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous Iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and Iron deficiency. J Am Coll Cardiol. 2008;51:103–112. doi: 10.1016/j.jacc.2007.09.036.[DOI] [PubMed] [Google Scholar]
  41. Usmanov RI, Zueva EB, Silverberg DS, Shaked M Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21:236–242[PubMed]
  42. Gaber R, Kotb NA, Ghazy M, Nagy HM, Salama M, Elhendy A. Tissue Doppler and strain rate imaging detect improvement of myocardial function in Iron deficient patients with congestive heart failure after Iron replacement therapy. Echocardiography. 2012;29:13–18.